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To the Editor,
The quite recent emergence of the SARS-CoV-2 pandemic
precludes long-term investigations of the immunologic
response towards this new pathogen. Depending on the
pathogen, serological persistence has been shown to last for
months to years, as for SARS-CoV or other human corona-
viruses (HCoV) [1]. Antibody responses to SARS-CoV-2 can
be detected in most infected individuals 14 days after the
symptom onset [2–4]. Recent reports are inconsistent
regarding the persistence of antibodies directed against
SARS-CoV-2 [5, 6]. These differences may be explained by
multiple reasons but are more probably related to method-
ological issues than real different immunogenic effects. The
aim of this study was to evaluate the long-term kinetics of
anti-SARS-CoV-2 antibodies in a population of RT-PCR
confirmed positive SARS-CoV-2 subjects and to describe the
kinetics of antibodies in hospitalized patients compared to
the one of non-hospitalized patients, including asymptom-
atic individuals.
A total of 197 patients with a confirmed SARS-CoV-2
RT-PCR were retrospectively included from March 21 to
October 27, 2020. Demographic of patient participants are
present in Supplementary Table 1. A total of 314 serum
samples was analyzed for the detection of anti-SARS-CoV-2
antibodies. The World Health Organization (WHO) clinical
progression scalewasuse to categorizepatients according to
disease severity (score 1 = asymptomatic, non-hospitalized;
score 2–3 = mild disease, non-hospitalized; score >3 = mod-
erate-severe disease, hospitalized) [7]. Information of
symptomonsetwas gathered in clinicalfiles of patients and/
or by contacting the medical practitioners. Blood samples
were collected into serum-gel or in lithium-heparin plasma
tubes (BD Vacutainer® tubes, Becton Dickinson, New Jer-
sey, USA) according to standardized operating procedures.
Samples were centrifuged for 10 min at 1,885 × g
(ACU Modular® Pre-Analytics, Roche Diagnostics®). The
Elecsys anti-SARS-CoV-2 nucleocapsid (NCP) electro-
chemiluminescent immunoassay (ECLIA) (Cobas e801,
Roche Diagnostics®, Basel, Switzerland) for the in vitro
qualitative detectionof total antibodies (IgG, IgMand IgA) to
SARS-CoV-2 was used. The test result is given as a cut-off
index (COI). According to the manufacturer, a result <1.0 is
considered negative while a result ≥1.0 is considered posi-
tive.Anoptimizedcut-off of 0.165was also consideredbased
on our previous validation [8] which has been confirmed by
a recent study performed by the National SARS-CoV-2
Serology Assay Evaluation Group (i.e. 0.128) [9]. The speci-
ficity of the test was excellent in several independent eval-
uations (99.8–100%) [8–11]. The RT-PCR for SARS-CoV-2
determination in respiratory samples (nasopharyngeal swab
samples) was performed on the LightCycler® 480 Instru-
ment II (Roche Diagnostics®) using the LightMix®Modular
SARS-CoV E-gene set.
Samples were subdivided according to the following cat-
egories since symptomonset, 0–1week: 44 sera; 1–2weeks: 30
sera; 2–4weeks: 60 sera; 4–6weeks: 18 sera; 6–11weeks days:
*Corresponding author: Jonathan Douxfils, Department of Pharmacy,
University of Namur 5000 Namur, Belgium; and Qualiblood sa, Namur,
Belgium, Phone:+3281 724391, E-mail: jonathan.douxfils@unamur.be.
https://orcid.org/0000-0002-7644-5298
Julien Favresse, Department of Laboratory Medicine, Clinique St-Luc
Bouge, Namur, Belgium; andDepartment of Pharmacy, NamurResearch
Institute for LIfe Sciences, University of Namur, Namur, Belgium
Marc Elsen, Christine Eucher and Kim Laffineur, Department of
Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
Sandrine Van Eeckhoudt and Jean-Baptiste Nicolas, Department of
Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium
Constant Gillot and Jean-Michel Dogné, Department of Pharmacy,
Namur Research Institute for LIfe Sciences, University of Namur, Namur,
Belgium
Clin Chem Lab Med 2020; aop
47 sera; 11–17 weeks: 57 sera; 17–26 weeks: 34 sera and
26–32 weeks: 24 sera. The antibody kinetics was determined
separately for hospitalized and non-hospitalized patients. In
asymptomatic patients, the day of RT-PCR positivity was used
instead of the day of symptom onset. A kinetics for patients
that had at least 3 blood samplingwith a last collection time at
more than 7 weeks since symptom onset was also evaluated
separately (10 non-hospitalized and 11 hospitalized patients).
Descriptive statistics were used to analyze the data.
Themean COI results (and 95%CI) were plotted against the
different timeframes. Sensitivity was defined as the pro-
portion of correctly identified COVID-19 positive patients
initially positive by RT-PCR SARS-CoV-2 determination.
Smoothing splines with four knots were used to estimate
the time kinetics curve in hospitalized (WHO score >3) and
non-hospitalized patients (WHO score 2–3). Dunn’s multi-
ple comparisons test was used to assess potential differ-
ences between sampling timings. Data analysis was
performed using GraphPad Prism® software (version
9.0.0, California, USA). p-value<0.05 was used as a sig-
nificance level. The study fulfilled the Ethical principles of
the Declaration of Helsinki.
In symptomatic patients, a gradual increase in anti-
body titers up to the last timepoint was observed
(Figure 1). We confirm that sampling before 2 weeks does
not permit to identify previous or ongoing infection due to
insufficient sensitivity. However, within the first week, the
positivity trend was higher in hospitalized patients
(i.e. 50%) compared to non-hospitalized patients
(i.e. 20%), an observation already made by Long et al. [12]
and by Gillot et al. [13]. From 4 to 6 weeks, excellent
sensitivities were observed (Table 1, Figure 1). Individual
results for hospitalized patients were largely above the
manufacturer’s cut-off. In non-hospitalized patients, one
asymptomatic subject did not developed antibodies
against the NCP (Figure 1A).
A trend towards higher antibody titers in hospitalized
patientswas also observed fromweeks6 to 11. Thedifference
was higher if considering weeks 17 to 32 (Figure 1B). Other
studies also reported higher levels of antibodies in patients
with more severe disease [2, 14–16]. Of the 21 patients for
which at least three independent blood drawn were avail-
able for aminimal follow-up period of 7weeks, a decrease in
antibody titer was observed for 4 non-hospitalized patients
out 10 (40%). In hospitalized patient, the titer gradually
increased to reach a plateau without any decrease
(n=11; 100%) (Supplementary Figure 1). Nevertheless, the
association was not found to be significant in our study
(p>0.05).
Importantly, the antibody kinetics may vary ac-
cording to the type of assay considered. Recent studies
are in line with the current results and also found a
sustained antibody response against the NCP antigen
using the Roche total antibody assay, on a lower follow-
up period (i.e. 3–4 months) [15, 17]. A sustained antibody
response against the receptor-binding domain (RBD)
antigen, as assessed by theWantai and the Siemens total
antibody assays, was also observed up to 4 months
[15, 17]. A decrease in anti-RDB IgG and anti-spike IgG
levels was similarly observed over a period of up to
5 months in recent reports [6, 14, 15, 18, 19]. A significant
decrease in sensitivity was also found using the Abbott




Figure 1: Anti-SARS-CoV-2 titers and long-term kinetics.
(A) Anti-SARS-CoV-2 titers (mean COI and 95% CI) from symptom
onset in hospitalized (blue points) and non-hospitalized
(orange points) COVID-19 patients (timeframe inweeks). Grey points
correspond to asymptomatic patients that had a positive RT-PCR.
(B) Long-term kinetics of anti-SARS-CoV-2 in hospitalized
(blue points) and non-hospitalized (orange points) COVID-19
patients (timeframe in weeks). Smoothing splines with four knots
were used to estimate the time kinetics curve (mean standard± error
of the mean). Asymptomatic patients were excluded from the
analysis.
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The sustained antibody response as measured with total
antibody assays (NCP and RBD) compared to IgG assays may
be due to the additional response of non-IgG antibody iso-
types. The reasons for the differences in assay performance
over time for assays targeting the same antigen remain
however unclear [17]. Whether the antibodies measured with
commercial assays has a neutralizing capacity is paramount
to indicate the potential level of protective immunity against
SARS-CoV-2 infection. Antibody titers generated with avail-
able assays correlated differently with neutralizing antibody
titers [17, 20–22]. TheRoche assaywas theweaker predictor of
neutralizing capacity (r=0.56, p=0.0001) compared to the
Abbott assay (NCP IgG) (r=0.69, p<0.0001), Siemens assay
(RDB total antibodies) (r=0.74, p<0.001), and the S1/S2-based
DiaSorin assay (S1/S2 IgG ) (r=0.84, p<0.0001) [17]. Jahrs-
dörfer et al. and Padoan et al. confirm that the weaker cor-
relation was observed using the Roche assay [11, 22], and
McAndrews et al. found that 86% of individuals positive for
RBD-directed antibodies exhibited neutralizing capacity,
whereas only 76% of positive NCP-directed antibodies
exhibited neutralizing capacity [23]. The fact that anti-NCP
assays have the lowest neutralizing capacity could be ex-
pected, as neutralizing antibodies are directed to the spike
protein responsible for enabling cell entry. Indeed, a strong
correlation between levels of anti-RBD or anti-spike anti-
bodies and neutralizing capacity has been found in inde-
pendent evaluations [5, 6, 14, 19, 24]. Neutralizing capacity
remained robust from 1 to 5 months in several studies [14, 19,
20], although modest declines at 3–5 months were observed
by Wajnberg et al. and Isho et al. [5, 18]. Other studies how-
ever observed a significant decrease of 2 to 4-fold, in
neutralizing capacity up to 3 months [16, 17, 25–27].
It is important to keep in mind that some patients may
develop anti-spike or anti-RBD antibodies but may not have
detectable neutralizing antibodies. These are only correla-
tion studies which are not related to direct measures of
neutralizing capacity [17]. The fact that neutralizing anti-
bodies constitute a major protective mechanism against
SARS-CoV-2 infection deserves that further investigation are
done in this area to assess to long-term inhibition capacity of
SARS-CoV-2 antibodies [5, 9, 17]. The contribution of B cells
and T cells to immunity to SARS-CoV-2 should also be more
explored and it seems important to remind that previous
exposure to SARS-CoV-2 might not guarantee total immu-
nity inall cases since reinfectionwithSARS-CoV-2havebeen
described [28, 29].
In conclusion, we found a gradual increase in anti-NCP
total antibody titers for up to 32 weeks since symptom
onset. Even if some non-hospitalized patients showed a
slight tendency towards a decrease of their antibody titer,
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hospitalized or non-hospitalized patients after one week
from symptom onset and last at least 7.5 months. Although
the majority of asymptomatic patients (95%) developed a
sustained antibody response, one patient did not devel-
oped antibodies 11 weeks after the RT-PCR positivity sup-
porting the claim that caution is advised when interpreting
anti-SARS-CoV-2 antibodies in asymptomatic subjects.
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